The corporate, which was based in 2017, stated that its immune profiling platform, which offers deep insights into the T-cells of the human immune system, is already intensely engaged in COVID-19 associated packages on three continents. It additionally has established collaborations with a number of vaccine growth firms, together with the San Diego-based Arcturus which is working scientific trials in Singapore.
ImmunoScape’s expertise was based mostly on work begun at Stanford College, and continued at A*STAR of Singapore (a statutory board below the Ministry of Commerce and Business). The corporate has acquired help from A*STAR and its commercialization arm A*ccelerate, in addition to Enterprise Singapore.
ON THE RECORD
“There may be an pressing want to know how the T-cell immune response contributes to COVID-19 immunity and may be leveraged for vaccine design,” stated ImmunoScape co-founder and Chief Working Officer Dr. Alessandra Nardin.
“In international collaborations with Massachusetts Common Hospital, College of Parma (Italy), and Duke-NUS, we’re evaluating COVID-19 sufferers and recovered people. We’re constructing a big knowledge set on human T-cell response to COVID-19, in an effort to develop new therapies and higher vaccines with our companions.”
“As a Singapore-based agency supported by the Company for Science Expertise and Analysis (A*STAR), our workforce has deep expertise assessing T-cell immune response to dengue, hepatitis B, and different viruses. It was clear that we should present deep help to COVID-19 vaccine growth on this international disaster,” stated ImmunoScape co-founder and CEO Choon Peng Ng, previously a senior govt at A*STAR.